Her treatment consisted of rhubarb pills and an infusion of orange peels. Now, 181 years later, multiple myeloma remains incurable, with most patients eventually relapsing or developing treatment ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...

Gut microbiome analysis of patients with multiple myeloma receiving idecabtagene vicleucel (ide-cel) therapy revealed specific bacterial species linked to treatment response and toxicity outcomes.

Bispecific antibodies enhance immune response by targeting myeloma and immune cells, showing high efficacy in multiple myeloma treatment. Tecvvayli, Talvey, and Elrexfio demonstrate significant ...

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: Diagnosis also required -- and still does -- the ...

He sought a second opinion at Fred Hutch Cancer Center, where a full body scan revealed that Crow had multiple myeloma. “I didn’t know what that was,” said Crow. “All I knew was that I had an ...

March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for multiple myeloma—a blood ...

The recommendation is for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma ...

Here’s my take on myeloma-related studies that I’m excited about now and in the year ahead, with a focus on smoldering multiple myeloma (SMM), newly diagnosed disease, and first relapse.

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial Presented in part at the ...

And obviously then, moving not just to immunotherapies, but non-immune approaches that can augment the options for patients with multiple myeloma.